Understanding Peptides: From Research to Real Life
Part 2: How GLP-1 Medications Work: It’s About More Than Appetite
Published September 2026 • By Dr Anne Wells, ND, FMCP-M • 10 min read
In Part 1 of Understanding Peptides: From Research to Real Life, we explored what peptides are, why GLP-1 medications belong to this larger family, and why they have become such an important area of medicine.
New to the series? Start with Part 1 to learn what peptides are and why GLP-1 medications belong to this fascinating family.
Now let's take the next step: What are these medications actually doing inside the body?
You’ve probably heard that medications like Ozempic®, Wegovy®, Mounjaro®, and Zepbound® help people lose weight because they make them less hungry.
That’s true, but it’s nowhere near the whole story.
As GLP-1 medications have become more popular, so have oversimplified explanations about how they work. You may have heard that they simply “shut off hunger,” “paralyze the stomach,” or work by making people too nauseated to eat.
The real physiology is much more interesting.
GLP-1 medications give us a fascinating window into something we’ve historically oversimplified: why we get hungry, why we feel full, and why regulating weight can be much more difficult for some people than for others.
Every time we eat, a complex conversation takes place between the gut, brain, pancreas, stomach, hormones, and nervous system. GLP-1 is one of the signals helping coordinate that conversation (Drucker, 2025).
GLP-1 medications don’t simply make you eat less. They change some of the biological signals that influence hunger, fullness, digestion, and blood sugar.
And when we understand what GLP-1 actually does, it becomes much easier to understand why these medications can affect far more than appetite.
What Does GLP-1 Normally Do?
GLP-1 stands for glucagon-like peptide-1.
It’s a hormone your body already makes naturally, primarily in specialized cells in the intestine.
When you eat, nutrients entering the digestive tract trigger the release of GLP-1.
You can think of it as one of the body’s “food has arrived” signals.
GLP-1 helps tell several parts of your body what to do next. It helps the pancreas respond appropriately to rising blood sugar levels, influences how quickly food moves through the stomach, and communicates with brain regions involved in hunger and fullness (Holst, 2024; Drucker, 2025).
Natural GLP-1 doesn’t stick around very long. The body breaks it down within minutes.
Medications such as semaglutide are designed to activate the same GLP-1 receptor while remaining active much longer. Tirzepatide goes a step further: it activates both GLP-1 and GIP receptors, which is why it is technically considered a dual GIP/GLP-1 receptor agonist (Drucker, 2025).
In Part 1, we introduced these basic actions. Now let's look at what they actually mean inside the body.
Your Brain: Why Hunger Isn’t Just Willpower
This may be the most important part of the GLP-1 story.
Your brain is constantly receiving information from throughout your body.
When did you last eat? How much energy is available? Is food entering your digestive tract?
What’s happening with your blood sugar? Have you eaten enough?
A network of hormones and nerves helps answer those questions, and GLP-1 is one of the signals involved.
GLP-1–responsive pathways communicate with brain regions that regulate hunger, fullness, and energy balance. The gut and brain also communicate through neural pathways, including signals involving the vagus nerve (Holst, 2024; Drucker, 2025).
For someone taking a GLP-1 medication, the change may feel surprisingly ordinary. They may simply notice that smaller portions feel like enough; they aren’t thinking about their next meal as soon; snacking becomes less appealing; or cravings don't feel quite as loud.
Some people describe this as having less “food noise.” It isn't a formal medical diagnosis, but the phrase resonates because it describes something that can otherwise be difficult to explain.
Hunger isn’t simply a matter of willpower. It is regulated by a complex biological conversation between the brain, gut, hormones, and nervous system.
That distinction matters.
GLP-1 medications aren't simply helping someone “try harder” to eat less. They're changing some of the biological signaling that influences the desire to eat in the first place.
The Stomach: How GLP-1 Affects Digestion
You’ve probably also heard that GLP-1 medications “slow down your stomach.”
There is some truth to that.
GLP-1 receptor agonists can slow gastric emptying, meaning food may move from the stomach into the small intestine more slowly. This can contribute to feeling full after eating and can affect how quickly glucose from a meal reaches the bloodstream (Jalleh et al., 2024).
But here's where the explanation often goes wrong:
GLP-1 medications don't work simply because food sits in your stomach longer.
The effect on gastric emptying varies from person to person and between medications. It may also become less pronounced over time with some longer-acting GLP-1 medications (Jalleh et al., 2024).
Yet people can continue losing weight.
That tells us the brain, appetite, satiety, and other metabolic signals do a lot of the work, too.
Feeling sick is not the goal of GLP-1 treatment. Nausea is a potential side effect, not proof that the medication is working.
The goal is to find a treatment approach that supports healthier appetite and metabolic regulation while still allowing someone to eat well, stay hydrated, exercise, get enough protein, and nourish their body.
The Pancreas: Insulin, Glucagon, and Blood Sugar
This part helps explain why GLP-1 medications were used for diabetes long before most people associated them with weight loss.
After you eat, glucose enters your bloodstream.
Your pancreas responds by releasing insulin, which helps move glucose out of the bloodstream so your cells can use or store it.
GLP-1 helps strengthen that response, but importantly, it does so primarily when blood glucose is elevated (Drucker, 2021; Drucker, 2025).
This is called a glucose-dependent insulin response.
GLP-1 also influences another hormone called glucagon. One of glucagon's jobs is telling the liver when to release stored glucose. When blood sugar is already elevated after eating, GLP-1 can help reduce inappropriate glucagon secretion (Drucker, 2025).
Put simply:
Food comes in → blood sugar rises → GLP-1 helps the body respond more appropriately.
But it isn't just the pancreas participating. The stomach, intestines, brain, pancreas, liver, and nervous system are all communicating.
GLP-1 works less like a single switch and more like part of a communication network connecting the gut, brain, pancreas, and metabolism.
Satiation vs. Satiety: What's the Difference?
Here's a distinction most of us have experienced without realizing there are actually words for it.
Satiation is the feeling that happens while you're eating:
“I've had enough. I can stop now.”
Satiety is what happens afterward:
“I'm still satisfied. I don't need to eat again yet.”
Those two processes have a big influence on how much we eat over the course of a day.
GLP-1 signaling participates in appetite and meal-related signaling, helping explain why people taking these medications may not simply report being “less hungry.” They may feel satisfied with less food and stay satisfied longer afterward (Holst, 2024).
For someone who has spent years trying to manage portions while feeling genuinely hungry, that's a meaningful difference.
Why Do GLP-1 Medications Lead to Weight Loss?
The short answer is straightforward:
Most people eat less.
The interesting part is why.
Traditional dieting often asks someone to consciously restrict food despite the body pushing back with hunger.
GLP-1 medications can change some of those hunger and satiety signals.
Instead of:
“I'm hungry, but I'm not allowed to eat.”
The experience may become:
“I'm satisfied. I really don't need any more.”
Research suggests that reduced energy intake is one of the primary drivers of weight loss with GLP-1–based therapies, with changes in brain appetite signaling, satiation, satiety, gastrointestinal function, and metabolic regulation all contributing (Drucker, 2021; Holst, 2024; Drucker, 2025).
The important difference isn't simply eating less. It's that eating less may no longer require fighting the same intensity of biological hunger.
Protecting Muscle During Weight Loss
There is another side of GLP-1 treatment that deserves more attention.
Losing weight and losing body fat aren't exactly the same thing.
With substantial weight loss, some lean tissue can be lost along with body fat.
That's particularly important during perimenopause, menopause, and later adulthood, when maintaining muscle and bone becomes increasingly important.
So the goal shouldn't be:
How little can I eat?
It should be:
How can I improve metabolic health while protecting muscle, nutrition, strength, and long-term health?
That means paying attention to adequate protein intake, resistance training, hydration, micronutrient intake, sleep, digestive health, and overall food quality (Drucker, 2025).
The medication is one tool. Protecting muscle, nourishing the body, and building sustainable habits are still the foundation.
Common Misconceptions About GLP-1 Medications
“They’re just appetite suppressants.”
Not quite.
Reduced appetite is certainly part of the story, but GLP-1–based medications also influence insulin and glucagon, gastric emptying, gastrointestinal signaling, and brain pathways involved in hunger, fullness, and energy regulation (Drucker, 2025; Moiz et al., 2025).
“They work because they make you nauseated.”
No. Nausea is a potential side effect, not the goal.
Gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation can occur, particularly when starting treatment or increasing the dose. But someone does not need to feel sick for a GLP-1 medication to work (Jalleh et al., 2024).
Persistent or severe gastrointestinal symptoms should be discussed with the prescribing clinician rather than interpreted as proof that the medication is “working.”
“They paralyze your stomach.”
That’s an oversimplification.
GLP-1 receptor agonists can slow gastric emptying, meaning food may move from the stomach into the small intestine more slowly. The degree of this effect varies depending on the medication, dose, treatment duration, and the individual (Jalleh et al., 2024).
Slowed gastric emptying is an important part of GLP-1 physiology, but it does not mean that everyone taking these medications develops a “paralyzed stomach.”
“They’re basically insulin.”
They’re not.
Insulin and GLP-1 medications both affect blood sugar, but they work differently. GLP-1 receptor activation primarily increases insulin secretion when glucose is elevated. It also influences glucagon, appetite, gastric emptying, and communication between the gut and brain (Holst, 2024; Drucker, 2025).
“If you need medication to lose weight, you didn’t try hard enough.”
This misunderstands the biology of obesity.
Obesity is a chronic, progressive disease, not a failure of willpower. The Obesity Society recognizes obesity as a complex disease that, without effective treatment, can progress over time and increase the risk of other chronic health conditions (The Obesity Society, 2019).
Body weight is influenced by far more than personal choices alone. Genetics, hormones, appetite signaling, brain pathways, sleep, medications, environment, energy expenditure, and many other factors can influence how easily someone gains weight, loses weight, or maintains weight loss.
Research into GLP-1 physiology has reinforced another important point: the drive to eat is biologically regulated. Hunger, fullness, and the ability to remain satisfied after eating involve complex communication between the gut, brain, hormones, and nervous system (Holst, 2024).
Hunger isn’t a character flaw!
“Once you’re taking a GLP-1, the medication does all the work.”
Definitely not.
A medication can change appetite and metabolic signaling. It can’t build muscle, provide adequate protein, improve sleep, keep you hydrated, or create a nutrient-dense diet.
Those pieces still matter, and they may become even more important when appetite is significantly reduced.
The goal isn’t simply to eat as little as possible. It’s to use the medication, when appropriate, as part of a broader strategy to improve metabolic health while protecting nutrition, muscle, strength, and long-term health.
From Research to Real Life
The more we learn about GLP-1, the harder it becomes to describe these medications as simply “weight-loss drugs.”
They’ve given researchers a fascinating look at how closely connected hunger, digestion, blood sugar, hormones, and the brain really are.
Every time we eat, the body is processing far more information than we consciously realize. The gut communicates with the brain. The pancreas responds to changing glucose levels. Hormones signal whether energy is available. The brain helps determine whether we should keep eating, or whether we’ve had enough.
GLP-1 is one part of this remarkably complex system.
That doesn’t mean GLP-1 medications are right for everyone, and it doesn’t mean nutrition, exercise, sleep, and other lifestyle factors suddenly stop mattering.
But for the right person, these medications may change some of the biological signals that have made weight management difficult in the first place (Holst, 2024; Drucker, 2025).
GLP-1 medications aren’t simply telling people to eat less. They’re helping us better understand why we eat in the first place.
And that may be one of the most interesting things this new era of metabolic medicine is teaching us.
Wondering if a GLP-1 Medication Is Right for You?
GLP-1 medications can be powerful tools, but they aren't one-size-fits-all. A personalized approach should consider your medical history, metabolic health, hormones, nutrition, lifestyle, goals, and the bigger picture of your health.
Coming Next
Part 3: Beyond Weight Loss, What Else Are Researchers Learning About GLP-1 Medications?
The story of GLP-1 medications is quickly expanding beyond blood sugar and weight.
Research has already demonstrated important benefits in areas such as cardiovascular and kidney health, while other potential applications are still being studied (Drucker, 2025).
In Part 3, we’ll look beyond the number on the scale and explore where the evidence is strongest, what researchers are investigating now, and which claims may be getting ahead of the science.
Because with GLP-1 medications, as with peptides in general, there’s an important difference between promising research and proven medicine.
Ready to Learn More?
If you’re wondering whether a GLP-1 medication, or another evidence-based approach to metabolic health, may be appropriate for you, individualized care can help determine which options make sense based on your health history, goals, laboratory findings, and overall needs.
Adaptive Wellness provides personalized naturopathic and functional medicine care through telemedicine throughout Washington State.
About the Author
Anne Wells, ND, FMCP-M, is a licensed naturopathic physician and functional medicine practitioner providing evidence-based, personalized care through Adaptive Wellness. Her approach focuses on identifying and addressing the underlying factors that contribute to symptoms and chronic health concerns, rather than looking at each symptom in isolation. She integrates conventional medical evaluation with functional medicine principles, including nutrition, lifestyle, hormone and metabolic health, and targeted laboratory testing. Her clinical interests include perimenopause and menopause, hormone optimization, metabolic health and weight management, GLP-1 medications, digestive and gut health, thyroid disorders, and healthy aging.
Follow Adaptive Wellness for more evidence-based information on hormones, metabolic health, digestive health, GLP-1 medications, and healthy aging.
This article is part of the educational series Understanding Peptides: From Research to Real Life.
Interested in the Science?
For readers who would like to explore the research in more detail, the scientific reviews referenced throughout this article are listed below.
References
Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nature Reviews Drug Discovery. 2025;24(8):631–650. DOI: 10.1038/s41573-025-01183-8. PMID: 40281304. (PubMed)
Holst JJ. GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management. Nature Metabolism. 2024;6(10):1866–1885. DOI: 10.1038/s42255-024-01113-9. PMID: 39160334. (Nature)
Jalleh RJ, Rayner CJ, Hausken T, Jones KL, Camilleri M, Horowitz M. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. The Lancet Gastroenterology & Hepatology. 2024;9(10):957–964. DOI: 10.1016/S2468-1253(24)00188-2. PMID: 39096914. (PubMed)
Moiz A, Filion KB, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation. The American Journal of Medicine. 2025;138(6):934–940. DOI: 10.1016/j.amjmed.2025.01.021. PMID: 39892489. (PubMed)
This article is intended for educational purposes only and is not a substitute for individualized medical advice, diagnosis, or treatment. Medications should be prescribed and monitored by an appropriately licensed healthcare professional.
GLP-1 medications aren’t simply telling people to eat less. They’re helping us better understand why we eat in the first place.
—is strong enough to serve as the final visual takeaway before Coming Next. It mirrors the style of Part 1 nicely without overusing the treatment.
Comments